Abstract | PURPOSE OF REVIEW:
Vancomycin has been the cornerstone of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections. This review describes new MRSA-active antibiotics that have recently been introduced and highlights emerging resistance. RECENT FINDINGS: SUMMARY: Several new MRSA-active agents are now approved for use, although much of the data is derived from treatment of acute bacterial skin and skin structure infections or pneumonia. Further studies are required for more invasive infections, such as bacteremia and endocarditis.
|
Authors | Natasha E Holmes, Benjamin P Howden |
Journal | Current opinion in infectious diseases
(Curr Opin Infect Dis)
Vol. 27
Issue 6
Pg. 471-8
(Dec 2014)
ISSN: 1473-6527 [Electronic] United States |
PMID | 25211361
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Acetamides
- Anti-Bacterial Agents
- Cephalosporins
- Glycopeptides
- Lipoglycopeptides
- Oxazolidinones
- Tetrazoles
- ceftobiprole
- Vancomycin
- tedizolid
- Linezolid
- oritavancin
|
Topics |
- Acetamides
(administration & dosage)
- Anti-Bacterial Agents
- Cephalosporins
(administration & dosage)
- Cost-Benefit Analysis
- Drug Administration Routes
- Drug Therapy, Combination
- Glycopeptides
(administration & dosage)
- Humans
- Linezolid
- Lipoglycopeptides
- Methicillin-Resistant Staphylococcus aureus
(drug effects)
- Microbial Sensitivity Tests
- Oxazolidinones
(administration & dosage)
- Severity of Illness Index
- Skin Diseases, Bacterial
(drug therapy, immunology, prevention & control)
- Staphylococcal Infections
(drug therapy, immunology, prevention & control)
- Tetrazoles
(administration & dosage)
- Vancomycin
(administration & dosage)
|